Patents Examined by James Douglas Schultz
-
Patent number: 9809642Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.Type: GrantFiled: May 27, 2016Date of Patent: November 7, 2017Assignee: Crystal Bioscience Inc.Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
-
Patent number: 6921845Abstract: Mice that are deficient in p53 are found to have memory disorders and/or behavioral disorders such as increased anxiety. A method of using p53-deficient mice to screen compounds for memory restoring activity and/or anti-anxiety activity is described.Type: GrantFiled: July 26, 1999Date of Patent: July 26, 2005Assignee: Molecular Engines LaboratoriesInventors: Robert Amson, Jean-Michel Lassalle, Adam Telerman
-
Patent number: 6884787Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of transforming growth factor-beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding transforming growth factor-beta 3. Methods of using these compounds for modulation of transforming growth factor-beta 3 expression and for treatment of diseases associated with expression of transforming growth factor-beta 3 are provided.Type: GrantFiled: July 14, 2001Date of Patent: April 26, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brett P. Monia, Susan M. Freier
-
Patent number: 6784163Abstract: The present invention provides methods of inhibiting cationic amino acid transport by means of antisense and antibody technology specific for the CAT2 transporter. Further, the present invention provides methods of treating a disease characterized by undesirable levels of nitric oxide.Type: GrantFiled: January 27, 1999Date of Patent: August 31, 2004Inventor: Carol L. MacLeod
-
Patent number: 6774227Abstract: The present invention relates to methods of treating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (MIF). The invention also relates to therapeutic compositions comprising factors which inhibit or neutralize MIF activity, such as, MIF antisense RNA molecules and MIF monoclonal antibodies and derivatives or analogs thereof. The invention further relates to the uses of such compositions and methods for the treatment of malignancies, including, but not limited to, B and T cell lymphomas.Type: GrantFiled: October 24, 1996Date of Patent: August 10, 2004Assignee: Cytokine PharmaSciences, Inc.Inventors: Richard J. Bucala, Jason Chesney
-
Patent number: 6770455Abstract: The present invention relates to metal-containing ribonucleotide polypeptides (RNP) and processes for their production, their use and medicaments containing ribonucleotide polypeptides or their molecular-biological equivalent structures and/or parts and/or derivatives.Type: GrantFiled: January 16, 2001Date of Patent: August 3, 2004Assignee: FraunhoferInventors: Stefan Kiesewetter, Eckehard Kuhn, Bridgitte Koch-Pelster, Herwig Brunner
-
Patent number: 6770753Abstract: The present invention provides antisense phosphorothioate oligonucleotides that specifically inhibit the translation of heparanase. The invention also provides various methods of reducing angiogenesis and metastasis of tumors in a subject using said antisense phosphorothioate oligonucleotides. Finally the invention provides pharmaceutical compositions comprising the said antisense phosphorothioate oligonucleotides as active ingredients.Type: GrantFiled: July 5, 2001Date of Patent: August 3, 2004Assignee: The Trustees of Columbia University in the City of New YorkInventor: Cy Stein
-
Patent number: 6743780Abstract: A system is described which utilizes a novel system of repressor titration for maintenance of a plasmid useful in gene therapy and production of a recombinant protein. The system utilizes a transformed host cell containing a plasmid including an operator susceptible to binding by a repressor expressed in trans, a first chromosomal gene encoding the repressor, and a second chromosomal gene that is functionally associated with an operator and essential for cell growth, wherein the plasmid is present in the cell in sufficient numbers to titrate the repressor such that the essential gene is expressed, thereby permitting cell growth.Type: GrantFiled: November 12, 1999Date of Patent: June 1, 2004Assignee: Cobra Biologics LimitedInventors: Julian A. J. Hanak, Steven G. Williams, Scott D. Gorman, David J. Sherratt
-
Patent number: 6727064Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: GrantFiled: January 11, 2001Date of Patent: April 27, 2004Assignee: ISIS Pharmaceuticals, Inc.Inventor: James G. Karras
-
Patent number: 6713457Abstract: The invention provides strategy for suppressing expression of an endogenous gene, wherein said strategy comprises providing suppression effectors able to bind to the non-coding regions of a gene to be suppressed, to prevent the functional expression thereof. The suppression effectors may be antisense nucleic acids, and the non-coding regions can include the transcribed but non-translated regions of a gene. The strategy can also introduce a replacement gene.Type: GrantFiled: September 21, 1998Date of Patent: March 30, 2004Inventors: Gwenyth Jane Farrar, Peter Humphries, Paul Francis Kenna
-
Patent number: 6692910Abstract: Methods of reducing gene expression, protein production and messenger RNA output in a cell are disclosed. Also disclosed is a method for delivering a selected ribozyme to a target mRNA in a cell. The methods are useful for prophylactic and therapeutic purposes.Type: GrantFiled: July 27, 1998Date of Patent: February 17, 2004Assignee: The University of ConnecticutInventors: David W. Rowe, Mary Louise Stover, Akin Beckley
-
Patent number: 6673918Abstract: Method for one-pot deprotection of RNA molecules.Type: GrantFiled: September 21, 2001Date of Patent: January 6, 2004Assignee: Sirna Therapeutics, Inc.Inventors: Laurent Bellon, Christopher T. Workman
-
Patent number: 6667293Abstract: The present invention provides a method of reducing the immunostimulatory effects of certain phosphorothioate oligonucleotides used to treat pathogen-mediated disease states and other medical conditions. Immunostimulatory effects of phosphorothioate oligonucleotides are reduced in accordance with the method of the invention by administering the phosphorothioate oligonucleotide in a therapeutic formulation which includes at least one cyclodextrin to a mammal afflicted with the disease or condition being treated. The immune response of the mammal is also monitored in the method of the invention.Type: GrantFiled: September 12, 1995Date of Patent: December 23, 2003Assignee: Hybridon, Inc.Inventors: Qiuyan Zhao, Jamal Temsamani, Sudhir Agrawal
-
Patent number: 6656688Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p65 subunit. Methods of using these compounds for modulation of NF-kappa-B p65 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p65 subunit are provided.Type: GrantFiled: May 24, 2001Date of Patent: December 2, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
-
Patent number: 6620585Abstract: The present invention relates to methods of measuring cellular proliferation using ectoenzymes such as membrane-bound chitobiase (N,N′-diacetylchitobiase) and nucleic acids for use in such methods.Type: GrantFiled: August 2, 2000Date of Patent: September 16, 2003Assignee: Elitra Pharmaceuticals, Inc.Inventor: Judith W. Zyskind
-
Patent number: 6602858Abstract: A nucleic acid catalyst comprising at least one L-nucleotide substitution.Type: GrantFiled: March 19, 2001Date of Patent: August 5, 2003Assignee: Ribozyme Pharmaceuticals, Inc.Inventor: Leonid Beigelman
-
Patent number: 6586180Abstract: A method for making a directed antisense library against a target transcript is described. A cDNA of the target transcript is cloned in an appropriate cloning vector. Next, a plurality of deletion derivatives of the cloned cDNA is prepared such that the deletions serially extend into the cDNA from one end thereof. The resulting deletion library is then treated such that cDNA is removed from the other end of each cDNA insert, thus obtaining a fragment library having fragments of a selected size. A catalytic core is then inserted into each fragment of the fragment library, resulting in the directed antisense library. An illustrative antisense gene in the hammerhead ribozyme catalytic core. Plasmids for making the antisense library, plasmids and methods for making the fragment library, and a method for identifying target sites for antisense-mediated gene inhibition are also described.Type: GrantFiled: December 4, 2000Date of Patent: July 1, 2003Assignee: University of UtahInventors: Duane E. Ruffner, Michael L. Pierce, Zhidong Chen
-
Patent number: 6562569Abstract: The present invention provides arrays having associated modified oligonucleotides that selectively bind to DNA or RNA, methods of making such arrays, assays for using such arrays, and the like. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.Type: GrantFiled: March 13, 2000Date of Patent: May 13, 2003Assignee: Oligos Etc. Inc.Inventor: Roderic M. K. Dale
-
Patent number: 6537973Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. In preferred embodiments, the oligonucleotides contain one or more chemical modifications. Methods of modulating PKC expression and of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression using oligonucleotides targeted to PKC are disclosed.Type: GrantFiled: December 18, 2001Date of Patent: March 25, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Nicholas M. Dean, Jon T. Holmlund, F. Andrew Dorr
-
Patent number: 6528262Abstract: A method for enrichment of natural antisense mRNA which involves hybridization of cDNA obtained from sense RNA with cDNA obtained from antisense RNA, followed by DNA polymerase treatment of the sense-antisense hybrid DNA molecule. A natural antisense library can be generated by cloning of sense-antisense hybrid DNA molecules in a vector.Type: GrantFiled: October 6, 2000Date of Patent: March 4, 2003Assignee: Quark Biotech, Inc.Inventors: Shlomit Gilad, Paz Einat, Avital Grossman